Exacerbation reduction data with benralizumab in subgroups of patients with severe eosinophilic asthma (SEA) from Central Europe and Baltics (BREEZE)

<bold>Background:</bold> RCT have demonstrated the efficacy of benralizumab in treating patients (pts) with SEA. Exacerbation reduction data from real-world studies in Central Eastern Europe and Baltics are scarce. <bold>Aim:</bold> To describe changes in the annualized rate of exacerbation (AER) in SEA pts initiated on benralizumab in real-life practice. <bold>Methods:</bold> BREEZE is a retrospective, observational study of adults with SEA receiving benralizumab in Bulgaria, Czech Republic, Hungary, Lithuania and Romania. AER before benralizumab start, and after 16&48 weeks (W) were calculated overall and in key baseline (BL) subgroups. <bold>Results:</bold> 381 pts, mean age 39 years at first asthma diagnosis and 56 years at benralizumab start; 66% female. At BL: median blood eosinophils 580 cells/μL (87%³300), 25% (96/381) pts on maintenance OCS use (median 10 mg/day prednisone equivalent, 68%>5 mg/day), 9% (34/381) with prior biologic use. Baseline AER (95% CI) was 3.05 (2.9-3.2), reducing to 0.22 (0.2-0.3) at W48. Overall relative reduction in AER at W16 and W48 was 92% and 93%, respectively, and 82–94% across key subgroups (Fig 1) <bold>Conclusion:</bold> SEA pts initiated on benralizumab in real-life setting obtained significant reductions of AER overall and in subgroups. <fig><object-id>erj;64/suppl_68/PA5357/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> Fig 1 Relative reduction in AER from baseline to weeks 16&48 following benralizumab start in SEA pts overall and by BL subgroups Funding: AstraZeneca